ArticleBMC infectious diseases2016
Factors associated with clinical outcome in 25 patients with avian influenza A (H7N9) infection in Guangzhou, China.
Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- CFTR as a therapeutic target for severe lung infection.American journal of physiology. Lung cellular and molecular physiology · 2025Review
- The pathogenesis of influenza in intact alveoli: virion endocytosis and its effects on the lung's air-blood barrier.Frontiers in immunology · 2024Review
- Knowledge toward COVID-19 in children among undergraduate students at the beginning of COVID-19 era.Nursing open · 2023Article
- Comparison of acute respiratory distress syndrome in patients with COVID-19 and influenza A (H7N9) virus infection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Green Synthesis-Mediated Nanoparticles and Their Curative Character Against Post COVID-19 Skin Diseases.Current pharmacology reports · 2022Review
- Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection.The American journal of pathology · 2021Article
- A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment.The Science of the total environment · 2020Review
- Clinical Insights into the Gastrointestinal Manifestations of COVID-19.Digestive diseases and sciences · 2020Review
- The "Three Italy" of the COVID-19 epidemic and the possible involvement of SARS-CoV-2 in triggering complications other than pneumonia.Journal of neurovirology · 2020Review
- The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.Military Medical Research · 2020Review
- Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19).International journal of biological sciences · 2020Review
- Combination Therapy Targeting Platelet Activation and Virus Replication Protects Mice against Lethal Influenza Pneumonia.American journal of respiratory cell and molecular biology · 2019Article
- Avian Influenza A (H7N9) and related Internet search query data in China.Scientific reports · 2019Article
- Veno-venous extracorporeal membrane oxygenation for patient with a history of open cholecystectomy and acute respiratory distress syndrome caused by coinfection of avian influenza A (H7N9) and Epstein-Barr virus.Chinese medical journal · 2019Article
- Clinical indices and mortality of hospitalized avian influenza A (H7N9) patients in Guangdong, China.Chinese medical journal · 2019Article
- Neutrophils Induce a Novel Chemokine Receptors Repertoire During Influenza Pneumonia.Frontiers in cellular and infection microbiology · 2019Article
- Article
- The Role of Extracellular Histones in Influenza Virus Pathogenesis.The American journal of pathology · 2018Article
- Impacts of age and gender at the risk of underlying medical conditions and death in patients with avian influenza A (H7N9): a meta-analysis study.Therapeutics and clinical risk management · 2018Article
- Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.Antiviral research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuangzhou reported its first laboratory-confirmed case of influenza A (H7N9) on January 10, 2014. A total of 25 cases were reported from the first wave of the epidemic until April 8, 2014. The fatality rate was much higher than in previous reports. The objective of the current work was to describe the clinical and epidemiological characteristics of A (H7N9) patients in Guangzhou and explore possible reasons for the high fatality rate.
methodsClinical and epidemiological information regarding A (H7N9) cases in Guangzhou was collected through review of medical records and field research. Data regarding clinical and laboratory features, treatment, and outcomes were extracted.
resultsOf the 25 patients, 84 % (21/25) had one or more underlying diseases. Fifteen patients (60.0 %) developed moderate to severe acute respiratory distress syndrome (ARDS), and 14 (56 %) died of the ARDS or multiorgan failure. Patients with longer delay between onset of illness and initiation of oseltamivir treatment were more likely to develop ARDS. Elevated C-creative protein, aspartate aminotransferase, creatine kinase, and lymphocytopenia predicted a higher risk of developing ARDS.
conclusionsThe presence of underlying diseases and clinical complications predicted poor clinical outcome. Early oseltamivir treatment was associated with a reduced risk of developing ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.